Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 839-849 , November 2008

Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides

  • Wouter A.P. Breeman

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC Rotterdam's 3015 CE Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 10 7035317.
    • ,
  • A.C. Fröberg

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC Rotterdam's 3015 CE Rotterdam, The Netherlands
    • ,
  • E. de Blois

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC Rotterdam's 3015 CE Rotterdam, The Netherlands
    • ,
  • A. van Gameren

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC Rotterdam's 3015 CE Rotterdam, The Netherlands
    • ,
  • M. Melis

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC Rotterdam's 3015 CE Rotterdam, The Netherlands
    • ,
  • M. de Jong

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC Rotterdam's 3015 CE Rotterdam, The Netherlands
    • ,
  • T. Maina

      Affiliations

    • Molecular Radiopharmacy Section, I/R-RP, NCSR “Demokritos”, Athens, Greece
    • ,
  • B.A. Nock

      Affiliations

    • Molecular Radiopharmacy Section, I/R-RP, NCSR “Demokritos”, Athens, Greece
    • ,
  • J.L. Erion

      Affiliations

    • BioSynthema Inc., St. Louis, MO, USA
    • ,
  • H.R. Mäcke

      Affiliations

    • Radiological Chemistry, University Hospital Basel, Switzerland
    • ,
  • E.P. Krenning

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC Rotterdam's 3015 CE Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands

Received 15 August 2008 ,Revised 19 September 2008 ,Accepted 28 September 2008.

References 

  1. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644–647
  2. Behe M, Reubi JC, Nock B, Macke HR, Breeman WAP, Bernard HF, et al. Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours. Eur J Nucl Med Mol Imaging. 2005;32:P273
  3. Behe M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging. 2003;30:1140–1146
  4. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers. 2002;66:399–418
  5. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029–1044
  6. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000;27:1312–1317
  7. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med. 1998;25:481–490
  8. Good S, Walter MA, Waser B, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging. 2008;35:1868–1877
  9. Breeman WA, de Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917–920
  10. von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1209–1218
  11. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007;48:615–622
  12. Breeman WAP, De Blois E, van Gameren A, et al. In: Aspects of CCK-2 Receptor-Targeting with 111In-DOTA-MG11. Technetium, Rhenium and other metals in chemistry in nuclear medicine 7. Padova: SG Editoriali U Mazzi; 2006;p. 231–232
  13. Sosabowski JK, Lee M, Dekker BA, et al. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci. 2007;31:102–111
  14. de Jong M, Bakker WH, Bernard BF, et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 1999;40:2081–2087
  15. Nock BA, Maina T, Behe M, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med. 2005;46:1727–1736
  16. Fröberg A, Nock BA, Maina T, et al. Comparison of 3 radiolabelled peptides for CCK 2-receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;S109
  17. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem. 2001;12:7–34
  18. Breeman WA, Kwekkeboom DJ, De Blois E, de Jong M, Visser TJ, Krenning EP. Radiolabelled regulatory peptides for imaging and therapy. Anti-Cancer Agents in Medicinal Chemistry. 2007;7:345–357
  19. Maina T, Nock B, Nikolopoulou A, et al. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging. 2002;29:742–753
  20. Bernard BF, Krenning E, Breeman WA, et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 2000;21:1079–1085
  21. Breeman WA, Kwekkeboom DJ, Kooij PP, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med. 1995;36:623–627
  22. de Jong M, Breeman WA, Bernard BF, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693–698
  23. Dubreuil P, Fulcrand P, Rodriguez M, Laur J, Bali JP, Martinez J. ACE-like hydrolysis of gastrin analogs and CCK-8 by fundic mucosal cells of different species with release of the amidated C-terminal dipeptide. Biochim Biophys Acta. 1990;1039:171–176
  24. Dubreuil P, Fulcrand P, Rodriguez M, Fulcrand H, Laur J, Martinez J. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide. Biochem J. 1989;262:125–130
  25. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999;81:658–665
  26. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421–1429
  27. Breeman WA, de Jong M, Bernard BF, et al. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657–663
  28. Breeman WA, VanHagen MP, Visser-Wisselaar HA, et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J Nucl Med. 1996;37:108–117
  29. van Hagen PM, Breeman WA, Reubi JC, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med. 1996;23:1508–1513
  30. Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol. 2005;32:673–678
  31. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478–485
  32. Velikyan I, Beyer GJ, Langstrom B. Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554–560
  33. Blauenstein P, Pfeiffer G, Schubiger PA, et al. Chemical and biological properties of a cationic Tc-tetraamine complex. Int J Appl Radiat Isot. 1985;36:315–317
  34. Prakash S, Went MJ, Blower PJ. Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Nucl Med Biol. 1996;23:543–549
  35. Reubi JC, Waser B, Laderach U, et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology. 1997;112:1197–1205

PII: S0969-8051(08)00199-6

doi: 10.1016/j.nucmedbio.2008.09.006

Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 839-849 , November 2008

Article Tools

* Image Usage & Resolution